BioSpace News Archive

Congress made welcomed legislative attempts in the past to increase medical discovery such as enacting the Orphan Drug and Translational Research Acts, but they are very limited in scope; and the same holds true with, due to the COVID-19 pandemic, the Administration’s new rules regarding relaxation of regulations to enter clinical trials in national emergency situations.

Today, the U.S. Food and Drug Administration issued a Drug Safety Communication regarding known side effects of hydroxychloroquine and chloroquine, including serious and potentially life-threatening heart rhythm problems, that have been reported with their use for the treatment or prevention of COVID-19, for which they are not approved by the FDA.

-Appoints Sol J. Barer, Ph.D. as Chairman of the Board - Appoints Suzanne Bruhn, Ph.D. and Joseph Miller as Directors to the Board ROCKVILLE, Md., April 24, 2020 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare pediatric and orphan diseases, today announced that Dr. Sol J. Barer has been appointed as the Chairman of the Board as Dr. Simon Pedder steps down as Executive Chairman

Company’s subsidiary ViralClear recently submitted an Investigational New Drug application to the FDA for its Phase II clinical trial with Merimepodib as a treatment for COVID-19

According to the American Sleep Association, around 50-70 million adults in the U.S. are suffering from sleep disorders, 48.0% of the U.S. adults report snoring, and approximately 5.9 million U.S. adults were diagnosed with obstructive sleep apnea (OSA).

Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced the closing of its previously announced public offering of (i) 4,000,000 shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and (ii) common warrants to purchase up to 4,000,000 shares of common stock.

This week, Methodist Le Bonheur Healthcare announced it is participating in Mayo Clinic’s Expanded Access Protocol for Convalescent Plasma Program for treatment of patients with COVID-19.

Forward Pharma A/S (NASDAQ:FWP) (“We,” “Forward” or the “Company” and, together with its subsidiaries, the “Group”), today reported consolidated financial and operating results for the year ended December 31, 2019.

Quanterix Corporation (NASDAQ: QTRX), a company digitizing analysis to advance the science of precision health, today announced a call for proposals for the Simoa® Success Grant Program.

Hackensack Meridian Health, New Jersey’s largest and most comprehensive health network, conducted an observational real world study of more than 3,000 hospitalized COVID-19 patients and found that hypertension, the most common co-existing condition, does not have a major impact on survival from the infection when adjusted for age and other comorbid conditions.